Current regulatory systems for clinical trials in Japan: Still room for improvement

References

• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline Guideline for Good Clinical Practice E6(R1). June 1996. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed September 24, 2014
   Google Scholar
• Yanagawa H, Akaishi A, Miyamoto T, et al. Role of clinical research coordinators in promoting clinical trials of drugs for surgical patients. Int Arch Med 2008;1:26
   PubMedGoogle Scholar
• Saito K, Kodama Y, Ono S, et al. Reliability of Japanese clinical trials estimated from GCP audit findings. Int J Clin Pharmacol Ther 2008;46:415–420
   PubMed Web of Science ®Google Scholar
• Yanagawa H, Nishiya M, Miyamoto T, et al. Clinical trials for drug approval: a pilot study of the view of doctors at Tokushima University Hospital. J Med Invest 2006;53:292–296
   PubMedGoogle Scholar
• Ito-Ihara T, Hong JH, Kim OJ, et al. An international survey of physicians regarding clinical trials: a comparison between Kyoto University Hospital and Seoul National University Hospital. BMC Med Res Methodol 2013;13:130
   PubMed Web of Science ®Google Scholar
• Yanagawa H, Irahara M, Kawashima S, Kagawa S; Tokushima Network for Clinical Trials. The views of doctors on registration trials in a Japanese rural area: a survey of medical institutions registered to the Tokushima Network for Clinical Trials. J Int Med Res 2008;36:1117–1122
   PubMed Web of Science ®Google Scholar
• Tsuji K, Tsutani K. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations. J Clin Pharm Ther 2010;35:289–301
   PubMed Web of Science ®Google Scholar
• Shirotani M, Kurokawa T, Chiba K. Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan. J Clin Pharmacol 2014;54:753–764
   PubMed Web of Science ®Google Scholar
• Ueno T, Asahina Y, Tanaka A, et al. Significant differences in drug lag in clinical development among various strategies used for regulatory submissions in Japan. Clin Pharmacol Ther 2014;95:533–541
   PubMed Web of Science ®Google Scholar
• Honig PK. Recent trends and success factors in reducing the lag time to approval of new drugs in Japan. Clin Pharmacol Ther 2014;95:467–469
   PubMedGoogle Scholar
• Ministry of Health, Labour and Welfare of Japan. Research Guidelines. Available from: http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/hokabunya/kenkyujigyou/i-kenkyu/index.html (in Japanese). Accessed September 24, 2014
   Google Scholar
• U.S. Department of Health & Human Services. Federal policy for the protection of human subjects (‘Common Rule’). Available from http://www.hhs.gov/ohrp/humansubjects/commonrule/index.html. Accessed September 24, 2014
   Google Scholar
• The European Parliament and the Council of the European Union. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official J Eur Communities 2001;L121:34–44
   Google Scholar
• The European Parliament and the Council of the European Union. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Official J Eur Union 2014;L158:1–76
   Google Scholar
• Cyranoski D. Japan to offer fast-track approval path for stem cell therapies. Nature Med 2013;19:510
   PubMed Web of Science ®Google Scholar
• Sawata H, Tsutani K. Funding and infrastructure among large-scale clinical trials examining cardiovascular diseases in Japan: evidence from a questionnaire survey. J Med Res Methodol 2011;11:148
   PubMedGoogle Scholar
• Normile D. Tampered data cast shadow on drug trial. Science 2013;341:223
   PubMed Web of Science ®Google Scholar
• Blair G. Novartis faces charges in Japan over promotion of valsartan to doctors. Brit Med J 2014;348:g287
   PubMedGoogle Scholar
• Tang W, Fukuzawa M, Ishikawa H, et al. Review of the registration of clinical trials in UMIN-CTR from 2 June 2005 to 1 June 2010 - focus on Japan domestic, academic clinical trials. Trials 2013;14:333
   PubMedGoogle Scholar